In a 4-month period, 216 cases of acute viral hepatitis were diagnosed in adults at the Infectious Diseases Hospital, Athens, Greece. Twenty-six percent of these were hepatitis B surface antigen negative. A full set of clinical specimens was obtained from 19 of these patients, who were studied in depth for the etiology of their hepatitis. A The development of sensitive tests for a number of markers of infection with hepatitis B virus (HBV) and hepatitis A virus (HAV) has permitted the establishment of the etiology of viral hepatitis in a high proportion of cases with a reasonable degree of certainty. The application of such assays to clinical testing has resulted in the discovery of one or more hepatitis agents, the so-called non-A, non-B agents, that cause clinical and sometimes serious disease in humans (5, 15). Type non-A, non-B hepatitis has been most extensively studied in patients with posttransfusion hepatitis, in which up to 90% of the disease has a non-A, non-B etiology (1). However, there is evidence that non-A, non-B agents cause clinical disease in other settings, and the relative importance of types A, B, and non-A, non-B hepatitis agents in the etiology of all clinical hepatitis in different parts of the world is not known. This study provides preliminary data on the relative importance of such agents in one epidemiological setting: acute viral hepatitis in Athens, Greece. 
In a 4-month period, 216 cases of acute viral hepatitis were diagnosed in adults at the Infectious Diseases Hospital, Athens, Greece. Twenty-six percent of these were hepatitis B surface antigen negative. A full set of clinical specimens was obtained from 19 of these patients, who were studied in depth for the etiology of their hepatitis. A total of 7 of the 19 patients had serological evidence of hepatitis A virus infection, and 2 had evidence of recent hepatitis B virus infection. The remaining 10 patients lacked evidence of hepatitis A virus, hepatitis B virus, cytomegalovirus, or Epstein-Barr virus infection related to their illness and were classified as having type non-A, non-B hepatitis. Types A and non-A, non-B hepatitis were clinically similar in these adult patients. However, patients with type non-A, non-B hepatitis were, on the average, older and more likely to have received parenteral inoculations during the 6 months before contracting hepatitis. Approximately 76% of the 216 consecutive cases of acute viral hepatitis were probably type B, approximately 10% were probably type A, and approximately 14% were probably type non-A, non-B, although the latter two types may be underestimated because of the possibility of superinfection with these viruses in asymptomatic hepatitis B surface antigen carriers. Thus, all three types of viral hepatitis appear to be important in the etiology of liver disease in Athens, Greece.
The development of sensitive tests for a number of markers of infection with hepatitis B virus (HBV) and hepatitis A virus (HAV) has permitted the establishment of the etiology of viral hepatitis in a high proportion of cases with a reasonable degree of certainty. The application of such assays to clinical testing has resulted in the discovery of one or more hepatitis agents, the so-called non-A, non-B agents, that cause clinical and sometimes serious disease in humans (5, 15) . Type non-A, non-B hepatitis has been most extensively studied in patients with posttransfusion hepatitis, in which up to 90% of the disease has a non-A, non-B etiology (1 (13) , and by immune adherence hemagglutination (14) and the enzyme-linked immunosor-bent assay (ELISA) for anti-HAV (12) . In addition, the sera were tested by a new ELISA for the antibody to hepatitis B core antigen (anti-HB,) as described below. Paired sera that were positive for anti-HB, by the ELISA but were negative for anti-HB, by the passive hemagglutination assay were retested for anti-HB, by the AUSAB radioimmunoassay (Abbott Laboratories).
The ELISA for anti-HBc was performed by a modification of the previously reported ELISA for anti-HAV (12 (8, 10 ).
Stool samples were tested for HAV antigen by the ELISA as 5 and 20% suspensions clarified by centrifugation at 1,500 x g for 45 min. In addition, 3-ml samples of the 20% suspensions were clarified at 10,000 rpm for 30 min in a Beckman SW50.1 rotor and pelleted through 2 ml of 30% sucrose at 50,000 rpm for 4 h in the same rotor. The pellet was suspended in 0.3 ml of phosphatebuffered saline and tested for HAV antigen by the ELISA.
As shown in Table 1 , seven patients had serological findings consistent with HAV infection: they had anti-HAV with a titer range of 1:2,700 to 1:90,000 by the ELISA and less than 1:10 by immune adherence hemagglutination in an acute-phase serum. Four of these patients seroconverted by immune adherence hemagglutination. A fifth patient had HAV antigen detectable in an acute-phase stool specimen. Thus, five of the seven patients had confirmed HAV infection, and two probably had type A hepatitis. (2, 4, 7, 11) .
In the present study, we confirmed the difficulty of diagnosing type A hepatitis by the detection of HAV antigen in stool samples, even when a sensitive assay for the antigen is employed. Similarly, we confirmed the usefulness of combining the results of two assays for anti-HAV in diagnosing HAV infection.
Our finding that in a Greek population approximately 40% of adults with sporadic acute type non-B hepatitis requiring hospitalization had HAV infection and that the remaining 60% appeared to have type non-A, non-B hepatitis confirms previous reports from California and Australia that both of these agents, along with HBV, are important causes of clinical hepatitis (3, 9) . From the data presented it can 
